EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Nanosystems at Nexus: Navigating Nose-to-Brain Delivery for Glioblastoma Treatment

Tejas Girish Agnihotri, Akanksha Dahifale, Shyam Sudhakar Gomte, Biswajit Rout, Vasu Peddinti, Aakanchha Jain iD

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.4c00703 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Tejas Girish Agnihotri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER)-Ahmedabad, Palaj, Gandhinagar 382355, Gujarat, India. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms, Drug Delivery Systems, Nanoparticles. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 166 Literaturangaben. Gefördert von: Science and Engineering Research Board, Department of Science and Technology, Government of India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma multiforme (GBM) is considered to be one of the most devastating brain tumors with a shorter life expectancy. Several factors contribute to the dismal prognosis of GBM patients including the complicated nature of GBM, the ability of tumor cells to resist treatment, and the difficulty of delivering drugs to the brain because of barriers like the blood-brain barrier (BBB) and blood-tumor barrier (BTB). The unique challenges posed by the BBB in delivering therapeutic agents to the brain have led to the development of innovative nanotechnology-based approaches. By exploiting the olfactory/trigeminal pathway, nanosystems offer a promising strategy for targeted drug delivery to the brain, glioblastoma tumors in particular. This review contemplates varied nanocarriers, including polymeric nanoparticles, lipid-based nanosystems, in situ gel formulations, peptide, and stem cell-based nanoformulations, signifying their utility in brain targeting with minimal systemic side effects. Emerging trends in gene therapy and immunotherapy in the context of GBM treatment have also been discussed. Since safety is a paramount aspect for any drug product to get approved, this review also delves into toxicological considerations associated with intranasal delivery of nanosystems. Regulatory aspects and critical factors for the successful development of intranasal products are also explored in this review. Overall, this review underscores the significant advancements in nanotechnology for nose-to-brain delivery and its potential impact on GBM management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsDrug Delivery SystemsNanoparticlesAntineoplastic AgentsHumansBlood-Brain BarrierAnimalsAdministration, IntranasalDrug CarriersNanoparticle Drug Delivery SystemImmunotherapyGenetic Therapy

Stichwörter der Autor:innen

glioblastomaimmunotherapynanoparticlesnose-to-brain deliverytoxicity

Substanzen

Antineoplastic AgentsDrug CarriersNanoparticle Drug Delivery System

Autor:innen und Institutionen

  • Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER)-Ahmedabad, Palaj, Gandhinagar 382355, Gujarat, India.

ORCID-Profile: Aakanchha Jain

Förderung

  • Science and Engineering Research Board, Department of Science and Technology, Government of India

Zitieren

APA

Agnihotri, T. G., Dahifale, A., Gomte, S. S., Rout, B., Peddinti, V., & Jain, A. (2025). Nanosystems at Nexus: Navigating Nose-to-Brain Delivery for Glioblastoma Treatment. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00703

Vancouver

Agnihotri TG, Dahifale A, Gomte SS, Rout B, Peddinti V, Jain A. Nanosystems at Nexus: Navigating Nose-to-Brain Delivery for Glioblastoma Treatment. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.4c00703

BibTeX
@article{Agnihotri2025,
  author = {Agnihotri, Tejas Girish and Dahifale, Akanksha and Gomte, Shyam Sudhakar and Rout, Biswajit and Peddinti, Vasu and Jain, Aakanchha},
  title = {Nanosystems at Nexus: Navigating Nose-to-Brain Delivery for Glioblastoma Treatment},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.4c00703}
}
Kostenlos starten →